Cybin Inc. Common Stock H.C. Wainwright 28th Annual Global Investment Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello everyone. Good morning, and thank you for joining H.C. Wainwright's 28th Annual Global Investment Conference, held on September 14 to 16, 2026. My name is Patrick Trucchio. I am a senior healthcare analyst at H.C. Wainwright, and it is our pleasure to host you today. It is my pleasure to welcome Helus' CEO, Michael Halstead, as well as the CMO, Amir Inamdar. For those who are unfamiliar, Helus is a neuropsychiatry company pioneering next generation psychedelics and neuromodulators for mental health. Helus is currently conducting a phase III program evaluating its lead candidate, HLP003, a deuterated psilocin analog for adjunctive treatment of major depressive disorder, MDD, and top-line data is expected later this year in the fourth quarter. Maybe for those who are less familiar, maybe you could introduce us to Helus and where the company stands today.
Sure. Thank you, Patrick. Thank you everyone for joining us today. Michael Halstead, recently appointed CEO of Helus. I joined in August. Very excited to talk about Helus Pharma today. In terms of the company, as you said, we are a mental health-focused company, a platform. We have multiple programs. We are developing novel serotonergic agonists for the treatment of several different mental health indications. Our late-stage program, as you said, is our 003 program, that is deuterated psilocin, that we are in phase III development for the treatment of adjunctive major depressive disorder, MDD. Really important indication. I am sure we will dig into that a little later in the talk. That is in phase III development. Our first phase III is expected to read out in the fourth quarter of this year, so a very near term, important event. We also have our 004 program that is the molecule is DMT.
It is in development for generalized anxiety disorder, GAD.
Call participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring